
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen has demonstrated robust financial performance with a 40% increase in sales in the third quarter of 2025 compared to the same quarter in 2024, alongside double-digit growth in 16 products. The company's revenue guidance for FY25 has been raised to a range of $35.8 billion to $36.6 billion, indicating strong momentum in its established franchises. Furthermore, Amgen is investing in its research and development with an anticipated growth rate of over 20% in 2025, suggesting a commitment to innovation and long-term growth.
Bears say
Amgen is projected to experience only ~1% total revenue growth in 2026 compared to 2025, amidst anticipated worldwide sales declines of ~28% for Prolia and ~39% for Xgeva. Despite possessing a robust pipeline with emerging products like MariTide and olpasiran, there is limited visibility into their ability to counteract the erosion of the base business and the impending loss of exclusivity for key franchises. This forecast, combined with muted R&D spending growth and the challenges posed by emerging therapies, contributes to a negative outlook on Amgen's stock.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares